AIM OF THE STUDY: Inflammatory cytokines have been implicated in the pathophysiology of post cardiac arrest syndrome, including myocardial dysfunction and hypotension, often leading to multi-organ system dysfunction and death. We hypothesized that administration of infliximab after return of spontaneous circulation (ROSC) would ameliorate hypotension and myocardial dysfunction and prolong survival. METHODS: Domestic swine were anesthetized and instrumented. Balloon occlusion of the LAD coronary artery just distal to the first septal perforator was performed and VF followed spontaneously in all animals. After 7 min, chest compressions, defibrillation, and standard ACLS resuscitation was performed. Animals achieving ROSC (N=32) were randomized to receive infliximab (5 mg/kg, n=16) or vehicle (250 mL normal saline, n=16) immediately post-ROSC and survival and hemodynamics were monitored for 3 h. RESULTS: There were no differences in prearrest hemodynamic variables, TNF-α levels, or resuscitation variables between groups. Both groups demonstrated a time dependent decline in mean arterial pressure (MAP) and stroke work (SW) post-ROSC with a nadir at 1 h followed by recovery over hours 2 and 3. This decline was blunted in infliximab-treated swine (1-h between group difference in MAP 21 mm Hg, 95% CI 3-38 mm Hg and SW 6.7 gm-m, 95% CI 0.4-13 at 1 h). Left ventricular systolic dp/dt fell in the vehicle group (-437 mm Hg/s, 95% CI -183 to -690) but did not in the infliximab group. Tau rose only in the vehicle group (44 ms, 95% CI 1-87). Short-term survival was higher in the infliximab group (Kaplan-Meier p=0.022). CONCLUSIONS: Blockade of TNF-α in the immediate post-ROSC period improved survival and hemodynamic parameters in this swine model of ischemic VF.
AIM OF THE STUDY: Inflammatory cytokines have been implicated in the pathophysiology of post cardiac arrest syndrome, including myocardial dysfunction and hypotension, often leading to multi-organ system dysfunction and death. We hypothesized that administration of infliximab after return of spontaneous circulation (ROSC) would ameliorate hypotension and myocardial dysfunction and prolong survival. METHODS: Domestic swine were anesthetized and instrumented. Balloon occlusion of the LAD coronary artery just distal to the first septal perforator was performed and VF followed spontaneously in all animals. After 7 min, chest compressions, defibrillation, and standard ACLS resuscitation was performed. Animals achieving ROSC (N=32) were randomized to receive infliximab (5 mg/kg, n=16) or vehicle (250 mL normal saline, n=16) immediately post-ROSC and survival and hemodynamics were monitored for 3 h. RESULTS: There were no differences in prearrest hemodynamic variables, TNF-α levels, or resuscitation variables between groups. Both groups demonstrated a time dependent decline in mean arterial pressure (MAP) and stroke work (SW) post-ROSC with a nadir at 1 h followed by recovery over hours 2 and 3. This decline was blunted in infliximab-treated swine (1-h between group difference in MAP 21 mm Hg, 95% CI 3-38 mm Hg and SW 6.7 gm-m, 95% CI 0.4-13 at 1 h). Left ventricular systolic dp/dt fell in the vehicle group (-437 mm Hg/s, 95% CI -183 to -690) but did not in the infliximab group. Tau rose only in the vehicle group (44 ms, 95% CI 1-87). Short-term survival was higher in the infliximab group (Kaplan-Meier p=0.022). CONCLUSIONS: Blockade of TNF-α in the immediate post-ROSC period improved survival and hemodynamic parameters in this swine model of ischemic VF.
Authors: Ian G Stiell; George A Wells; Brian Field; Daniel W Spaite; Lisa P Nesbitt; Valerie J De Maio; Graham Nichol; Donna Cousineau; Josée Blackburn; Doug Munkley; Lorraine Luinstra-Toohey; Tony Campeau; Eugene Dagnone; Marion Lyver Journal: N Engl J Med Date: 2004-08-12 Impact factor: 91.245
Authors: Pierrick Cronier; Philippe Vignon; Koceila Bouferrache; Philippe Aegerter; Cyril Charron; François Templier; Samuel Castro; Rami El Mahmoud; Cécile Lory; Nicolas Pichon; Olivier Dubourg; Antoine Vieillard-Baron Journal: Crit Care Date: 2011-05-11 Impact factor: 9.097
Authors: Andreas Janata; Ingrid A M Magnet; Thomas Uray; Jason P Stezoski; Keri Janesko-Feldman; Samuel A Tisherman; Patrick M Kochanek; Tomas Drabek Journal: Resuscitation Date: 2014-02-12 Impact factor: 5.262
Authors: Abigail A Palmer; Jason P Stezoski; Keri Janesko-Feldman; Patrick M Kochanek; Tomas Drabek Journal: Exp Ther Med Date: 2022-04-08 Impact factor: 2.447
Authors: Mareen Braunstein; Martina Williamson; Thomas Kusmenkov; Jürgen Landes; Peter Biberthaler; Karl-Georg Kanz; Wolfgang Böcker; Viktoria Bogner Journal: Mediators Inflamm Date: 2017-12-27 Impact factor: 4.711